Retatrutide for Sale UK

Retatrutide for Sale UK — Research-Grade LY3437943

Retatrutide is one of the most studied investigational peptides of the past decade. As a triple hormone receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors, it has produced the highest weight-reduction figures ever recorded in a Phase 3 randomised controlled trial. For UK laboratories sourcing retatrutide for sale, purity documentation, batch testing, and domestic supply are non-negotiable.

Arma Peptides supplies Retatrutide 10mg and Retatrutide 30mg (ZONJERO) as lyophilised, research-grade vials — ≥99% purity, every batch HPLC-verified, Certificate of Analysis included. UK warehouse. Fast dispatch.

1. What Is Retatrutide (LY3437943)?

Retatrutide — development code LY3437943 — is a synthetic acylated peptide created by Eli Lilly. It is engineered as a once-weekly, long-acting multi-agonist targeting three metabolic hormone receptors simultaneously. This makes it structurally and pharmacologically distinct from all currently approved weight-management agents.

• CAS number: 2381272-75-7
• Molecular weight: ~4,720 Da
• Form: Acylated synthetic peptide (fatty diacid conjugate)
• Half-life: ~6 days (weekly dosing in trials)
• Development stage: Phase 3 (TRIUMPH programme, Eli Lilly, 2025–2026)

2. Triple Receptor Mechanism Explained

Retatrutide’s defining characteristic is simultaneous agonism at three distinct receptors:

GLP-1R (Glucagon-Like Peptide-1 Receptor)

Stimulates glucose-dependent insulin secretion, slows gastric emptying, reduces appetite via central satiety pathways. This is the mechanism shared with semaglutide and tirzepatide.

GIPR (Glucose-dependent Insulinotropic Polypeptide Receptor)

Enhances insulin response to meals, modulates adipocyte function, and contributes to lipid metabolism. Shared with tirzepatide but not semaglutide.

GCGR (Glucagon Receptor)

The differentiator. Glucagon receptor activation directly increases hepatic glucose output and thermogenesis — promoting energy expenditure at rest. This is why retatrutide’s metabolic ceiling in clinical data exceeds both semaglutide and tirzepatide. No currently approved weight-loss drug activates this receptor.

The synergistic interaction of all three receptor pathways produces a uniquely comprehensive metabolic profile: appetite suppression, improved insulin sensitivity, increased energy expenditure, and hepatic fat mobilisation acting simultaneously.^[1]

3. Research Data — Phase 2 & Phase 3 Trials

Phase 2 Trial (NEJM, 2023)^[2]

Published in the New England Journal of Medicine, the Phase 2 trial at the 12mg dose over 48 weeks reported:

• Average body weight reduction of ~24.2%
• >90% of participants lost ≥10% body weight
• ~46% lost ≥20% body weight
• Significant HbA1c reductions in participants with type 2 diabetes

Phase 3 — TRIUMPH-4 (2025)^[3]

The first Phase 3 readout — TRIUMPH-4 — was published December 2025. At 68 weeks on the 12mg dose:

• Average weight reduction: 28.7%
• 9mg dose: 26.4% average weight loss
• Met both co-primary endpoints (weight reduction + osteoarthritis pain reduction)

Phase 3 — TRIUMPH-1 (2025)^[4]

Eli Lilly’s pivotal obesity trial at 80 weeks on the 12mg dose:

• Average weight loss: 28.3% (~70.3 lbs / ~32kg)
• 45.3% of participants achieved ≥30% body weight reduction
• These are the highest weight-reduction figures ever recorded in a pharmaceutical RCT

Additional Research Areas (Active Trials)

• Type 2 diabetes: Phase 2 data shows clinically meaningful HbA1c reductions vs approved comparators
• MASLD / fatty liver disease: Significant liver fat reduction observed as secondary endpoint
• Cardiovascular outcomes: NCT06383390 ongoing
• Chronic low back pain: Phase 3 trial in obese participants (Lilly, 2025)

4. Retatrutide vs Semaglutide vs Tirzepatide

The additional glucagon receptor agonism is the mechanistic differentiator. GCGR activation increases hepatic glucose output and thermogenesis — promoting resting energy expenditure in a way that GLP-1/GIP dual agonists cannot replicate. This is why the metabolic ceiling observed with tirzepatide does not appear to apply to retatrutide in Phase 3 data.^[1,3]

5. Why Source Matters When Buying Retatrutide UK

The UK research peptide market has expanded rapidly alongside interest in incretin-class compounds. Not all suppliers meet the same standards. When sourcing retatrutide for sale in the UK, researchers should verify:

Purity Documentation

Retatrutide below ≥99% purity will compromise experimental outcomes and may contain synthesis by-products. Arma Peptides supplies retatrutide at ≥99% purity, with HPLC-verified batch data and a Certificate of Analysis on every order.

UK Warehouse vs Import

Overseas-sourced peptides introduce customs delays, cold-chain integrity risks, and extended transit times that degrade lyophilised compounds. Arma Peptides stock is held in a UK warehouse — typically dispatched within 1–2 working days.

UK Legal Status (2026)

Retatrutide has not received MHRA marketing authorisation and cannot be legally prescribed or dispensed as a medicine in the UK. It is a legitimate research compound available for in vitro laboratory research only. All Arma Peptides orders are sold strictly under these terms.

Form and Stability

Arma Peptides retatrutide is supplied as a lyophilised (freeze-dried) vial — the most stable form for laboratory storage. Lyophilised peptides retain integrity at −20°C for extended periods. Reconstitution should be performed under sterile conditions using bacteriostatic water.

6. Retatrutide Products — Arma Peptides UK

Browse the full catalogue in our peptide shop. Free delivery on orders over £200. Use code FIRST10% for 10% off your first order.

7. Storage & Handling

• Lyophilised (unopened): Store at −20°C, protected from light and moisture. Stable for 24+ months under proper conditions.
• After reconstitution: Store at 4°C, use within 14 days. Do not freeze reconstituted peptide.
• Reconstitution: Use bacteriostatic water (0.9% benzyl alcohol in sterile water) under aseptic conditions.
• Handling: Avoid repeated freeze-thaw cycles. Protect from UV light.

8. Frequently Asked Questions